文献速递青光眼

选择性激光小梁成形术与局部药物治疗作为青光眼初始治疗的头对头随机临床试验:青光眼初始治疗研究

Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial.
PubMed 文献 · Br J Ophthalmol · 2019-09-05

这项国际多中心随机对照试验将167例初治轻中度原发性开角型或剥脱性青光眼患者按1:1随机分为选择性激光小梁成形术(SLT)组和局部药物组,主要结局为青光眼特异性生活质量(GOAT)。24个月时两组GOAT均有组内改善,SLT组「社会福祉」域改善优于药物组;药物组眼压降低成功率绝对差高出18.6个百分点,但结膜充血和眼睑红斑更常见。

要点

  • 24个月时SLT组较药物组在GOAT「社会福祉」域改善更大(均值±标准误0.28±0.13,p=0.034)。
  • 24个月时药物组眼压降低成功率较SLT组绝对高18.6%(95%CI 3.0%至34.3%,p=0.022)。
  • 24个月时药物组结膜充血和眼睑红斑人数多于SLT组。

核心结论

  • 总体未发现SLT在改善青光眼特异性生活质量方面优于药物治疗的证据。
  • 药物组眼压降低更优,但该组眼睑红斑和结膜充血更常见。

研究设计与样本

  • 国际、纵向、多中心随机对照试验,初治轻中度原发性开角型或剥脱性青光眼患者按1:1随机分配至SLT组或局部药物组。
  • 共入选167例,SLT组83例、药物组84例;完成24个月随访145例(SLT组75例、药物组70例)。
  • 主要结局为采用青光眼结局评估工具(GOAT,342个条目、12个域)测量的青光眼特异性生活质量,按意向性分析在12个月和24个月进行。

主要发现

  • 两组在12个月和24个月两个时间点GOAT结局均较基线有显著组内改善。
  • 24个月时SLT组较药物组在「社会福祉」域组间改善更大(均值±标准误0.28±0.13,p=0.034)。
  • 24个月时药物组眼压降低成功率较SLT组绝对高18.6%(95%CI 3.0%至34.3%,p=0.022)。
  • 24个月时药物组结膜充血和眼睑红斑人数多于SLT组。

关键数值与推荐

  • 眼压降低成功定义为眼压较基线降低>25%。
  • GOAT含342个条目、12个域。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To determine if selective laser trabeculoplasty (SLT) is superior to topical medication as a first-line treatment for glaucoma on quality of life (QoL) and clinical outcomes. METHODS: In this international, longitudinal, multisite randomised controlled trial, treatment naïve mild-to-moderate primary open angle or exfoliation glaucoma patients were randomised 1:1 to SLT or topical medication. Glaucoma-specific QoL (primary outcome) was measured using the Glaucoma Outcomes Assessment Tool (GOAT; 342 items, 12 domains). Secondary outcomes included rate of successful intraocular pressure (IOP) reduction (>25% reduction from baseline) and presence of ocular surface disease including conjunctival hyperaemia and eyelid erythema. Our intention-to-treat analysis was performed at months 12 and 24. RESULTS: Of 167 enrolled patients, 83 and 84 were randomised to SLT and topical medication, respectively; and 145 (n=75 SLT, n=70 medication) completed 24-month follow-up. While both treatment arms achieved significant within-group gains in GOAT outcomes at both endpoints, SLT patients reported a greater between-group improvement in 'social well-being' compared with medication patients (mean±SE=0.28±0.13; p=0.034) at 24 months. At month 24, the rate of successful IOP reduction was 18.6% (95% CI 3.0% to 34.3%, p=0.022) higher (absolute difference) in the medication compared with SLT group. More individuals in the medication group had conjunctival hyperaemia and eyelid erythema compared with SLT at 24 months. CONCLUSION: Overall, we did not find evidence that SLT was superior to medication in improving glaucoma-specific QoL. While we found superior IOP reduction in the medication arm, eyelid erythema and conjunctival hyperaemia were more prevalent in these patients compared with the SLT group. TRIAL REGISTRATION: ACTRN12611000720910.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ang GS, Fenwick EK, Constantinou M, et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. Br J Ophthalmol. 2019. PMID: 31488427. doi:10.1136/bjophthalmol-2018-313396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。